Loading organizations...
§ Private Profile · Kuopio, Eastern Finland, Finland
Clinical-stage synthetic biology company using genetically engineered bacteria to treat chronic wounds and cancer.
Aurealis Pharma, now operating as Aurealis Therapeutics, is a clinical-stage synthetic biology company based in Zug, Switzerland, and Kuopio, Finland, that develops genetically engineered lactic acid bacteria to produce therapeutic proteins for chronic wounds and oncology. The biotechnology firm utilizes live bacteria as micro-factories to deliver treatments directly to disease sites, advancing its lead candidate AUP-16 through Phase 2 clinical trials for diabetic foot ulcers. Aurealis Pharma has secured over $20 million in total funding to date, including a recent CHF 8 million financing round closed in November 2024 to support its ongoing clinical pipeline and the AUP-55 oncology program. The company is backed by a syndicate of private and institutional investors, featuring recognizable financial entities such as Business Finland and Finnvera plc. Aurealis Pharma was founded in 2010 by Juha Yrjänheikki and Thomas Wirth.
Aurealis Pharma has raised $13.7M across 2 funding rounds.
Aurealis Pharma has raised $13.7M in total across 2 funding rounds.
Aurealis Pharma has raised $13.7M in total across 2 funding rounds.
Aurealis Pharma's investors include Finnvera.
Aurealis Pharma has raised $13.7M across 2 funding rounds. Most recently, it raised $7.8M Other Equity in February 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 12, 2019 | $7.8M Venture Round | — | Finnvera | Announced |
| Aug 29, 2017 | $5.9M Series A | — | Finnvera | Announced |